Related Content
- Gallup: Take Care Clinics top in customer service
- The Little Clinic adds new insurance provider to accepted plans
- FDA should consult advisory committees on DXM issue
- Bartell to cease filling Medicaid prescriptions at 15 locations
- Rite Aid takes a bite out of obesity; relaunches weight-loss program for New Year
SILVER SPRING, Md. The Food and Drug Administration has approved a drug for reducing relapses in patients with multiple sclerosis.
The FDA announced Wednesday the approval of Swiss drug maker Novartis’ Gilenia (fingolimod) capsules, saying it was the first oral drug that can slow the progression of disability in patients with MS and offered an alternative to injected drugs.
Around 400,000 people in the United States and 2.1 million worldwide have MS, according to the National Multiple Sclerosis Society.
